Description: CytoDyn Inc. is a clinical-stage biotechnology company. The Company is focused on the clinical development and commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The Company's lead product candidate, PRO 140, belongs to a class of HIV therapies known as entry inhibitors that block HIV from entering into and infecting certain cells. The Company's product pipeline also includes Cytolin and CytoFeline. Cytolin is a mouse monoclonal antibody developed to identify a specific type of immune cell called a cytotoxic T cell, or cytotoxic T lymphocyte (CTL). CytoFeline is an anti-lymphocyte function-associated antigen-1 (LFA-1) antibody for the treatment of Feline Immunodeficiency Virus (FIV) infection. PRO 140 blocks HIV from entering a cell by binding to a molecule called C-C chemokine receptor type 5 (CCR5). The Company has finished Phase II clinical trials for PRO 140 with demonstrated antiviral activity in man.
Home Page: www.cytodyn.com
1111 Main Street
Vancouver,
WA
98660
United States
Phone:
360 980 8524
Officers
| Name | Title |
|---|---|
| Mr. Antonio Migliarese CPA | CFO, Treasurer & Sec. |
| Mr. Cyrus Arman M.B.A., Ph.D. | Pres |
| Dr. Bernie Cunningham P.M.P., Ph.D. | VP of Operations |
| Mr. George Bitar | Head of Quality & Exec. Director |
| Dr. Kush Dhody | Sr. VP of Clinical Operations |
| Dr. Denis R. Burger | Scientific Consultant |
| Ms. Cristina De Leon | Investors |
Exchange: OTCQB
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 10.8108 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1066.0343 |
| Price-to-Sales TTM: | 1174.391 |
| IPO Date: | |
| Fiscal Year End: | May |
| Full Time Employees: | 23 |